Published in Women's Health Weekly, October 13th, 2005
Researchers in the United States conducted a study "to evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated."
"After four cycles of neoadjuvant docetaxel, the clinical response rate within the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.